Crossref
Ripretinib inhibits polyclonal drug-resistant KIT oncoproteins: the next step forward in gastrointestinal stromal tumor therapy
Gastrointestinal Stromal Tumor · 2023
DOI: 10.21037/gist-22-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Gastrointestinal Stromal Tumor, 2023. Verfasst von Maria Debiec-Rychter und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Debiec-Rychter, M., & Rutkowski, P. (2023). Ripretinib inhibits polyclonal drug-resistant KIT oncoproteins: the next step forward in gastrointestinal stromal tumor therapy. Gastrointestinal Stromal Tumor. https://doi.org/10.21037/gist-22-5
Vancouver
Debiec-Rychter M, Rutkowski P. Ripretinib inhibits polyclonal drug-resistant KIT oncoproteins: the next step forward in gastrointestinal stromal tumor therapy. Gastrointestinal Stromal Tumor. 2023. doi:10.21037/gist-22-5
BibTeX
@article{DebiecRychter2023,
author = {Debiec-Rychter, Maria and Rutkowski, Piotr},
title = {Ripretinib inhibits polyclonal drug-resistant KIT oncoproteins: the next step forward in gastrointestinal stromal tumor therapy},
journal = {Gastrointestinal Stromal Tumor},
year = {2023},
doi = {10.21037/gist-22-5}
}
EUVIMED